tiprankstipranks
Trending News
More News >

Compass Pathways Achieves Phase 3 Trial Success

Story Highlights
  • Compass Pathways achieved the primary endpoint in their Phase 3 COMP005 trial for treatment-resistant depression.
  • The COMP005 trial showed a significant reduction in symptom severity with COMP360, and results will be discussed with the FDA.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Compass Pathways Achieves Phase 3 Trial Success

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from COMPASS Pathways ( (CMPS) ).

Compass Pathways announced the successful achievement of the primary endpoint in their Phase 3 COMP005 trial, which evaluates the efficacy of COMP360 for treatment-resistant depression. The trial demonstrated a statistically significant reduction in symptom severity with a single dose of COMP360 compared to placebo. The company plans to discuss these findings with the FDA. The ongoing COMP005 trial involves 258 participants and aims to assess the safety and efficacy of a single dose of 25 mg COMP360 versus placebo. The COMP006 trial, running in parallel, compares different doses of COMP360 and is expected to provide additional data in the second half of 2026.

The most recent analyst rating on (CMPS) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on COMPASS Pathways stock, see the CMPS Stock Forecast page.

Spark’s Take on CMPS Stock

According to Spark, TipRanks’ AI Analyst, CMPS is a Neutral.

Compass Pathways demonstrates potential due to its strong equity position and progress in clinical trials. However, significant financial risks due to a lack of revenue and increasing operational costs weigh heavily on its performance. The stock’s upward momentum is promising, but valuation remains challenging due to negative profitability. The recent earnings call underscores both strategic progress and financial challenges, which tempers the overall outlook.

To see Spark’s full report on CMPS stock, click here.

More about COMPASS Pathways

Compass Pathways is a company operating in the mental health industry, focusing on developing treatments for difficult-to-treat mental health conditions. Their primary product is COMP360, a synthetic, proprietary formulation of psilocybin, which is under investigation for treatment-resistant depression (TRD).

Average Trading Volume: 1,205,189

Technical Sentiment Signal: Sell

Current Market Cap: $429.9M

For a thorough assessment of CMPS stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1